Published in Blood on January 16, 2007
Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Blood (2008) 1.89
Thrombin. Mol Aspects Med (2008) 1.80
The development of inflammatory joint disease is attenuated in mice expressing the anticoagulant prothrombin mutant W215A/E217A. Blood (2011) 1.71
Structural identification of the pathway of long-range communication in an allosteric enzyme. Proc Natl Acad Sci U S A (2008) 1.31
Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates. Arterioscler Thromb Vasc Biol (2013) 1.30
Engineering thrombin for selective specificity toward protein C and PAR1. J Biol Chem (2010) 1.09
Allostery in trypsin-like proteases suggests new therapeutic strategies. Trends Biotechnol (2011) 1.07
Recombinant human activated protein C: current insights into its mechanism of action. Crit Care (2007) 1.06
Mechanism of the anticoagulant activity of thrombin mutant W215A/E217A. J Biol Chem (2009) 0.95
Thrombin mutant W215A/E217A treatment improves neurological outcome and reduces cerebral infarct size in a mouse model of ischemic stroke. Stroke (2011) 0.94
Stabilization of the E* form turns thrombin into an anticoagulant. J Biol Chem (2009) 0.91
Slow thrombin is zymogen-like. J Thromb Haemost (2009) 0.90
Rigidification of the autolysis loop enhances Na(+) binding to thrombin. Biophys Chem (2011) 0.88
Activated protein C in sepsis: the promise of nonanticoagulant activated protein C. Curr Opin Hematol (2008) 0.86
Redesigning allosteric activation in an enzyme. Proc Natl Acad Sci U S A (2011) 0.82
Thrombin mutant W215A/E217A treatment improves neurological outcome and attenuates central nervous system damage in experimental autoimmune encephalomyelitis. Metab Brain Dis (2014) 0.81
Safety and antithrombotic efficacy of moderate platelet count reduction by thrombopoietin inhibition in primates. Sci Transl Med (2010) 0.81
Role of coagulation in the recruitment of colon adenocarcinoma cells to thrombus under shear. Am J Physiol Cell Physiol (2013) 0.78
Design of Factor XIII V34X activation peptides to control ability to interact with thrombin mutants. Biochim Biophys Acta (2011) 0.77
WEDGE: an anticoagulant thrombin mutant produced by autoactivation. J Thromb Haemost (2014) 0.77
Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med (2005) 8.55
Deaths: leading causes for 2002. Natl Vital Stat Rep (2005) 2.64
Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem (1994) 2.52
Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature (1992) 2.48
Rac1 is essential for platelet lamellipodia formation and aggregate stability under flow. J Biol Chem (2005) 2.07
Conversion of thrombin into an anticoagulant by protein engineering. Nature (1995) 1.98
Human protein C receptor is present primarily on endothelium of large blood vessels: implications for the control of the protein C pathway. Circulation (1997) 1.81
The impact of the inflammatory response on coagulation. Thromb Res (2004) 1.73
Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis. Pediatrics (2004) 1.60
Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood (2001) 1.51
Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) study. Catheter Cardiovasc Interv (2004) 1.47
Expression and function of the endothelial protein C receptor in human neutrophils. Blood (2003) 1.45
Safety and efficacy of low-dose intravenous enoxaparin and GP IIb/IIIa inhibitor therapy during PCI. J Invasive Cardiol (2003) 1.45
Functional mapping of the surface residues of human thrombin. J Biol Chem (1995) 1.38
Single amino acid substitutions dissociate fibrinogen-clotting and thrombomodulin-binding activities of human thrombin. Proc Natl Acad Sci U S A (1991) 1.35
Rational design of a potent anticoagulant thrombin. J Biol Chem (2000) 1.32
Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. A potential rapid mechanism for modulation of coagulation. J Clin Invest (1992) 1.27
Mice with a severe deficiency of the endothelial protein C receptor gene develop, survive, and reproduce normally, and do not present with enhanced arterial thrombosis after challenge. Thromb Haemost (2002) 1.23
Activation of protein C in vivo. J Clin Invest (1982) 1.20
The thrombin mutant W215A/E217A shows safe and potent anticoagulant and antithrombotic effects in vivo. J Biol Chem (2002) 1.19
Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates. J Clin Invest (1993) 1.17
Protein engineering thrombin for optimal specificity and potency of anticoagulant activity in vivo. Biochemistry (1996) 1.17
Direct detection of activated protein C in blood from human subjects. Blood (1992) 1.17
Recruitment of labelled monocytes by experimental venous thrombi. Thromb Haemost (2001) 1.11
Activated protein C induces the release of microparticle-associated endothelial protein C receptor. Blood (2004) 1.09
Inhibition of platelet-dependent thrombus formation by human activated protein C in a primate model. Blood (1989) 1.08
Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. J Am Coll Cardiol (2003) 1.02
The endothelial cell protein C receptor (EPCR) functions as a primary receptor for protein C activation on endothelial cells in arteries, veins, and capillaries. Biochem Biophys Res Commun (1999) 1.00
Endothelial protein C receptor-dependent inhibition of human eosinophil chemotaxis by protein C. J Allergy Clin Immunol (2003) 0.99
Functionally active thrombomodulin is present in human platelets. J Biochem (1988) 0.97
Human neutrophils synthesize thrombomodulin that does not promote thrombin-dependent protein C activation. Blood (1992) 0.96
Exogenous eosinophil activation converts PSGL-1-dependent binding to CD18-dependent stable adhesion to platelets in shear flow. Am J Physiol Cell Physiol (2003) 0.93
Adhesion of leukocytes to growing arterial thrombi. Thromb Haemost (1998) 0.93
ORG 10172: a low molecular weight heparinoid anticoagulant with a long half-life in man. Br J Clin Pharmacol (1987) 0.91
Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol (1999) 0.91
Identification of divalent metal ion-dependent inhibition of activated protein C by alpha 2-macroglobulin and alpha 2-antiplasmin in blood and comparisons to inhibition of factor Xa, thrombin, and plasmin. J Biol Chem (1991) 0.91
A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol (2002) 0.91
Limited generation of activated protein C during infusion of the protein C activator thrombin analog W215A/E217A in primates. J Thromb Haemost (2006) 0.90
A physiologic anti-inflammatory pathway based on thrombomodulin expression and generation of activated protein C by human mononuclear phagocytes. J Immunol (1996) 0.87
Challenge and rechallenge: drotrecogin alfa (activated)-induced prolongation of activated partial thromboplastin time in a patient with severe sepsis. Pharmacotherapy (2005) 0.82
New class of heparin derivatives with a potent antithrombotic effect and a very limited hemorrhagic activity. Thromb Res (1996) 0.80
Benefit of adding low molecular weight heparin to the conventional treatment of stable angina pectoris. A double-blind, randomized, placebo-controlled trial. Circulation (1993) 0.80
Functional assays for protein C activity and protein C inhibitor activity in plasma. Thromb Haemost (1989) 0.79
A recombinant hirudin (IK-HIR02) in healthy volunteers. I. Effects on coagulation parameters and bleeding time. Haemostasis (1996) 0.79
Stable and optimal anticoagulation is achieved with a single dose of intravenous enoxaparin in patients undergoing percutaneous coronary intervention. J Invasive Cardiol (2002) 0.79
Importance of platelets in neutrophil adhesion and vasoconstriction after deep carotid arterial injury by angioplasty in pigs. Arterioscler Thromb Vasc Biol (1997) 0.79
Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. Int J Cardiol (1999) 0.78
The haemorrhagic effect of low molecular weight heparins, dermatan sulphate and hirudin. Haemostasis (1996) 0.77
Effect of ketorolac and low-molecular-weight heparin individually and in combination on haemostasis. Blood Coagul Fibrinolysis (1999) 0.77
The prolonged bleeding time in hemophilia A: comparison of two measuring technics and clinical associations. Am J Clin Pathol (1985) 0.77
The effect of acetylsalicylic acid in 3 different formulations on in vitro and in vivo platelet function tests. An experimental study on healthy male volunteers. Scand J Haematol (1984) 0.77
Haemorrhagic effect of enoxaparin, a low molecular weight heparin. Comparison with unfractionated heparin in humans. Scand J Gastroenterol (1992) 0.76
Bleeding time in hemophilia A: potential mechanisms for prolongation. J Pediatr (1986) 0.76
Enoxaparin suppresses thrombin formation and activity during cardiopulmonary bypass in baboons. J Thorac Cardiovasc Surg (1998) 0.76
Three dimensional optical angiography. Opt Express (2007) 8.30
The cytoprotective protein C pathway. Blood (2006) 5.75
Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med (2003) 4.04
Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med (2007) 3.35
Endothelial and antithrombotic actions of HDL. Circ Res (2006) 2.68
Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nat Med (2004) 2.45
Factor XI contributes to thrombin generation in the absence of factor XII. Blood (2009) 2.31
Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3. Neuron (2004) 2.23
Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nat Med (2006) 2.22
Evolution of enzyme cascades from embryonic development to blood coagulation. Trends Biochem Sci (2002) 1.96
Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. Biochem J (2003) 1.91
Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Blood (2008) 1.89
Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. J Clin Invest (2009) 1.86
A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood (2010) 1.83
Factor XII inhibition reduces thrombus formation in a primate thrombosis model. Blood (2014) 1.81
Thrombin mutant W215A/E217A acts as a platelet GPIb antagonist. Arterioscler Thromb Vasc Biol (2007) 1.80
Role of Na+ and K+ in enzyme function. Physiol Rev (2006) 1.80
Molecular dissection of Na+ binding to thrombin. J Biol Chem (2004) 1.72
The development of inflammatory joint disease is attenuated in mice expressing the anticoagulant prothrombin mutant W215A/E217A. Blood (2011) 1.71
Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. Thromb Haemost (2013) 1.70
Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. Blood (2004) 1.68
Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions. J Biol Chem (2007) 1.67
Identification of coagulation factor XI as a ligand for platelet apolipoprotein E receptor 2 (ApoER2). Arterioscler Thromb Vasc Biol (2009) 1.64
Studies on the basis for the properties of fibrin produced from fibrinogen-containing gamma' chains. Blood (2005) 1.64
Numerical investigation of the effects of channel geometry on platelet activation and blood damage. Ann Biomed Eng (2010) 1.58
Protective signaling by activated protein C is mechanistically linked to protein C activation on endothelial cells. J Biol Chem (2006) 1.58
Pharmacological targeting of the thrombomodulin-activated protein C pathway mitigates radiation toxicity. Nat Med (2012) 1.58
Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates. Blood (2003) 1.55
Ion exchangers NHX1 and NHX2 mediate active potassium uptake into vacuoles to regulate cell turgor and stomatal function in Arabidopsis. Plant Cell (2012) 1.54
Optical quantification of cellular mass, volume, and density of circulating tumor cells identified in an ovarian cancer patient. Front Oncol (2012) 1.54
Histone deacetylase 6-mediated deacetylation of α-tubulin coordinates cytoskeletal and signaling events during platelet activation. Am J Physiol Cell Physiol (2013) 1.53
Cytoprotective protein C pathways and implications for stroke and neurological disorders. Trends Neurosci (2011) 1.53
Molecular imaging of inflammation and platelet adhesion in advanced atherosclerosis effects of antioxidant therapy with NADPH oxidase inhibition. Circ Cardiovasc Imaging (2012) 1.53
Exposure of R169 controls protein C activation and autoactivation. Blood (2012) 1.52
Inhibition of acute vascular thrombosis in chimpanzees by an anti-human tissue factor antibody targeting the factor X binding site. Thromb Haemost (2009) 1.51
Elevated plasma fibronectin levels associated with venous thromboembolism. Thromb Haemost (2008) 1.49
Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells. Proc Natl Acad Sci U S A (2008) 1.45
Effect of hyperhomocysteinemia on protein C activation and activity. Blood (2002) 1.45
Activated protein C targets CD8+ dendritic cells to reduce the mortality of endotoxemia in mice. J Clin Invest (2010) 1.41
Conformational selection or induced fit? A critical appraisal of the kinetic mechanism. Biochemistry (2012) 1.39
S6K1 and mTOR regulate Rac1-driven platelet activation and aggregation. Blood (2011) 1.39
Activated protein C: potential therapy for severe sepsis, thrombosis, and stroke. Semin Hematol (2002) 1.38
Impact of Hospital Admission Care At a Pediatric Unit: A Qualitative Study. Pediatr Nurs (2016) 1.38
Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant. Blood (2009) 1.36
Retracted Endogenous EPCR/aPC-PAR1 signaling prevents inflammation-induced vascular leakage and lethality. Blood (2009) 1.36
Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46. Blood (2012) 1.35
A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep (2013) 1.33
Activated protein C promotes neovascularization and neurogenesis in postischemic brain via protease-activated receptor 1. J Neurosci (2008) 1.33
Structural identification of the pathway of long-range communication in an allosteric enzyme. Proc Natl Acad Sci U S A (2008) 1.31
High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation (2005) 1.31
Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates. Arterioscler Thromb Vasc Biol (2013) 1.30
Microfluidics and coagulation biology. Annu Rev Biomed Eng (2013) 1.30
Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity. Eur J Neurosci (2009) 1.30
Molecular characterization of an extended binding site for coagulation factor Va in the positive exosite of activated protein C. J Biol Chem (2002) 1.30
Rapid kinetics of Na+ binding to thrombin. J Biol Chem (2006) 1.29
Functional recovery after embolic stroke in rodents by activated protein C. Ann Neurol (2005) 1.26
Quantification of cellular volume and sub-cellular density fluctuations: comparison of normal peripheral blood cells and circulating tumor cells identified in a breast cancer patient. Front Oncol (2012) 1.26
Measurement of single cell refractive index, dry mass, volume, and density using a transillumination microscope. Phys Rev Lett (2012) 1.26
The effect of a recombinant elastin-mimetic coating of an ePTFE prosthesis on acute thrombogenicity in a baboon arteriovenous shunt. Biomaterials (2006) 1.24
Crystal structures of murine thrombin in complex with the extracellular fragments of murine protease-activated receptors PAR3 and PAR4. Proc Natl Acad Sci U S A (2007) 1.23
Spatial distribution of factor Xa, thrombin, and fibrin(ogen) on thrombi at venous shear. PLoS One (2010) 1.22
Red blood cell-derived microparticles isolated from blood units initiate and propagate thrombin generation. Transfusion (2012) 1.22
The AtNHX1 exchanger mediates potassium compartmentation in vacuoles of transgenic tomato. Plant J (2009) 1.21
Conformational selection in trypsin-like proteases. Curr Opin Struct Biol (2012) 1.20
The thrombin mutant W215A/E217A shows safe and potent anticoagulant and antithrombotic effects in vivo. J Biol Chem (2002) 1.19
Laminin stimulates spreading of platelets through integrin alpha6beta1-dependent activation of GPVI. Blood (2005) 1.19
An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents. Stroke (2012) 1.18
Cytoprotective signaling by activated protein C requires protease-activated receptor-3 in podocytes. Blood (2011) 1.17
High-density lipoprotein and the risk of recurrent venous thromboembolism. Circulation (2007) 1.16
Evolution of peptidase diversity. J Biol Chem (2008) 1.16
Recombinant murine-activated protein C is neuroprotective in a murine ischemic stroke model. Blood Cells Mol Dis (2003) 1.15
Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. Proc Natl Acad Sci U S A (2014) 1.14
Platelet shape change and spreading. Methods Mol Biol (2012) 1.13
Small-molecule inhibitors of integrin alpha2beta1 that prevent pathological thrombus formation via an allosteric mechanism. Proc Natl Acad Sci U S A (2009) 1.13
Crystal structure of thrombin in a self-inhibited conformation. J Biol Chem (2006) 1.11
Activated protein C preserves functional islet mass after intraportal transplantation: a novel link between endothelial cell activation, thrombosis, inflammation, and islet cell death. Diabetes (2004) 1.11